Chronic treatment in vivo with β-adrenoceptor agonists induces dysfunction of airway β 2-adrenoceptors and exacerbates lung inflammation in mice

Rui Lin, Simone Degan, Barbara S. Theriot, Bernard M. Fischer, Ryan T. Strachan, Jiurong Liang, Richard A. Pierce, Mary E. Sunday, Paul W. Noble, Monica Kraft, Arnold R. Brody, Julia K.L. Walker

Research output: Contribution to journalArticle

28 Scopus citations

Abstract

BACKGROUND AND PURPOSE Inhalation of a β-adrenoceptor agonist (β-agonist) is first-line asthma therapy, used for both prophylaxis against, and acute relief of, bronchoconstriction. However, repeated clinical use of β-agonists leads to impaired bronchoprotection and, in some cases, adverse patient outcomes. Mechanisms underlying this β 2- adrenoceptor dysfunction are not well understood, due largely to the lack of a comprehensive animal model and the uncertainty as to whether or not bronchorelaxation in mice is mediated by β 2-adrenoceptors. Thus, we aimed to develop a mouse model that demonstrated functional β-agonist-induced β 2-adrenoceptor desensitization in the context of allergic inflammatory airway disease. EXPERIMENTAL APPROACH We combined chronic allergen exposure with repeated β-agonist inhalation in allergen-treated BALB/C mice and examined the contribution of β 2-adrenoceptors to albuterol-induced bronchoprotection using FVB/NJ mice with genetic deletion of β 2-adrenoceptors (KO). Associated inflammatory changes - cytokines (ELISA), cells in bronchoalevolar lavage and airway remodelling (histology) and β 2-adrenoceptor density (radioligand binding) - were also measured. KEY RESULTS β 2-Adrenoceptors mediated albuterol-induced bronchoprotection in mice. Chronic treatment with albuterol induced loss of bronchoprotection, associated with exacerbation of the inflammatory components of the asthma phenotype. CONCLUSIONS AND IMPLICATIONS This animal model reproduced salient features of human asthma and linked loss of bronchoprotection with airway pathobiology. Accordingly, the model offers an advanced tool for understanding the mechanisms of the effects of chronic β- agonist treatment on β-adrenoceptor function in asthma. Such information may guide the clinical use of β-agonists and provide insight into development of novel β-adrenoceptor ligands for the treatment of asthma.

Original languageEnglish (US)
Pages (from-to)2365-2377
Number of pages13
JournalBritish Journal of Pharmacology
Volume165
Issue number7
DOIs
StatePublished - Apr 1 2012
Externally publishedYes

Keywords

  • airway inflammation
  • airway remodelling
  • asthma
  • loss of bronchoprotection
  • mouse
  • receptor desensitization
  • β-adrenoceptor
  • β-agonist

ASJC Scopus subject areas

  • Pharmacology

Fingerprint Dive into the research topics of 'Chronic treatment in vivo with β-adrenoceptor agonists induces dysfunction of airway β <sub>2</sub>-adrenoceptors and exacerbates lung inflammation in mice'. Together they form a unique fingerprint.

  • Cite this

    Lin, R., Degan, S., Theriot, B. S., Fischer, B. M., Strachan, R. T., Liang, J., Pierce, R. A., Sunday, M. E., Noble, P. W., Kraft, M., Brody, A. R., & Walker, J. K. L. (2012). Chronic treatment in vivo with β-adrenoceptor agonists induces dysfunction of airway β 2-adrenoceptors and exacerbates lung inflammation in mice. British Journal of Pharmacology, 165(7), 2365-2377. https://doi.org/10.1111/j.1476-5381.2011.01725.x